AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06273774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study NCT06291441 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention (observational study)
Study NCT06591013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Transplantation of fresh fecal bacterial fluid into the ileocecum of patients with ulcerative colitis via the colonoscopic route
Study NCT06587685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-011Gel
Description: Twice daily for 52 weeks or 44 weeks
Study NCT06587685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Gel twice daily for 8 weeks
Study NCT06588179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1501+SHR-2005
Description: SHR-1501, instillation；SHR-2005, instillation
Study NCT06598839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha1
Description: subcutaneous injection of Tα1, 1.6mg each time, biw, for 3 months
Study NCT06595017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger points at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of magnesium sulphate
Study NCT06595017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine (drug)
Description: After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Lidocaine
Study NCT06595017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Saline
Study NCT06593613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RUBI-A
Description: The RUBI-A intervention includes 9 sessions covering Behavioral Principles, Prevention Strategies, Visual Supports, Reinforcement, Co-Regulation, Supporting Communication, Effective Instructions, Teaching Skills, and Generalization and Maintenance. RUBI teaches skills to help build a behavioral toolbox for challenging behaviors and adaptive skills. RUBI emphasizes: 1) tailoring the intervention to the specific individual; 2) identifying behavioral function instead of topography to inform behavioral strategy choice; 3) increasing appropriate behaviors; and 4) using positive behavioral supports,39,40 such as antecedent management (e.g., use of visual supports), reinforcement, and functional communication strategies to support independence, self-help, and safety skills.
Study NCT06593613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R-ISLEA
Description: R-ISLEA training focuses on increasing core knowledge and understanding of autism, but it does not provide specific guidance on behavioral strategies for managing challenging behaviors. Developed by autism experts at Drexel University in collaboration with autistic self-advocates, ISLEA is a commercially available psychoeducation program designed for educators, direct support staff, families, caregivers, and autistic individuals. If English is not the language of care for a dyad, subtitles in the preferred language will be provided for the webinars, and interpreters will be available for the live sessions.
Study NCT06596876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRG2010; Sustained-release Carbidopa/Levodopa administered placebo
Description: Subjects will receive HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo administered orally.
Study NCT06596876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained-release Carbidopa/Levodopa; HRG2010 placebo
Description: Subjects will receive Sustained-release Carbidopa/Levodopa and HRG2010 placebo administered orally.
Study NCT06603727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Gaming Rehabilitation Program 1
Description: Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
Study NCT06603727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Gaming Rehabilitation Program 2
Description: Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
Study NCT06423326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06423326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06423326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT06423326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06423326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT06423326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06423326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT06423326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic Surgical Procedure
Description: Undergo surgical resection
Study NCT06599450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Root form dental implant
Description: Placement of titanium endosteal root form threaded tapered two-piece dental implant to assist mandibular complete overdenture
Study NCT06590909 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser assisted PDT
Description: Comparative split face study: participants will be treated with fractional co2 laser on the whole face then applying topical insulin on the right side of the face and topical platelet rich plasma on the left side of the face.
Study NCT05156684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two placebo tablets daily
Study NCT05156684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two trental tablets daily
Study NCT05156684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive one zinc sulfate tablet daily
Study NCT05156684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc + pentoxifylline
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two pentoxifylline tablets+ one zinc tablet daily
Study NCT06306547 — intervention group
Intervention type: OTHER
Intervention: no interventions were involved
Description: no interventions were involved
Study NCT05857982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab
Description: Dexamethasone 20 mg/d, on the same day of daratumumab injection; Mitoxantrone hydrochloride liposome injection: 20 mg/m2, d1; Daratumumab: 16 mg/Kg, once a week for the first 8 weeks; then changed to once every two weeks; Each cycle is 4 weeks long and the maximum number of cycles is 6.
Study NCT06354231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DV
Description: 2.0 mg/kg, intravenously administered every 2 weeks
Study NCT06354231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3.0mg/kg, intravenously administered every 2 weeks
Study NCT06354231 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser surgery
Description: Subjects will receive 6 cycles of DV and toripalimab, followed by laser surgery to remove ureteral or renal pelvis tumors, followed by 12 cycles of DV and 1 year of toripalimab consolidation therapy.
Study NCT06470061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol, Quercetin, and Curcumin (RQC)
Description: 2000 mg Curcumin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~334 mg Resveratrol/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~60 mg Quercetin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)
Study NCT06470061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Curcumin
Description: 2000 mg Curcumin/day, taken twice daily for 7 days preceding each study visit (baseline and months 3, 6, 12, 18, and 24 for a total of 42 non-consecutive days over 24 months.
Study NCT05450094 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening Only
Description: The Screening Only intervention integrates enhancements to school-based mental health (SBMH). Each school's typical SBMH service delivery system will be enhanced with biweekly meetings of voluntary school teams (comprised of administrators, school counselors, general and special education teachers, and other school-employed mental health professionals) to 1) follow standardized evidence-based intervention decision making process to identify students with mental health risk, plan and/or refer for an evidence-based intervention, monitor intervention progress, and adjust intervention plans as needed; 2) administer teacher-rated and student self-report universal screening twice annually; 3) review screening and related school records data to identify students with mental health risk; and 4) review screening, referral, and receipt data to monitor progress of entire SBMH service delivery system.
Study NCT05450094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Screening
Description: The Enhanced Screening intervention involves the enhancements to school-based mental health (SBMH) of the Screening Only intervention with the addition of 3 empirically supported enhancements: 1) Voluntary school teams will review screening and service receipt data disaggregated by racial/ethnic subgroups to identify and problem solve inequities. 2) Unintentional bias training for voluntary school teams, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 3) Mental Health Literacy training for voluntary school teams in awareness and understanding of students' mental health well-being and need for intervention.
Study NCT04886895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Let's Move
Description: Motor intervention
Study NCT00057174 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Disease management of gastroesophageal reflux disease
Study NCT06244485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat tosylate
Description: Administered orally once daily
Study NCT06244485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: One IV infusion Q3W on Day 1 of each 21-day cycle
Study NCT06244485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: One IV infusion Q3W on Day 1 of each 21-day cycle.
Study NCT06596928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Elements T-Hero Platinum
Description: Participants will take two capsules daily for 90 days
Study NCT06596928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will take two placebo capsules daily for 90 days.
Study NCT06602154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin modified glass ionomer
Description: The product will be stored by investigators at room temperature in lock and key.~Product: Riva light cure RMGIC (HV) Composition: 18 mg orthodontic bonding paste and 6 ml enamel bond resin. Storage: Stored at room temperature and protected from humidity.~Usage: Steps for Resin-modified glass ionomer cement composite bonding:~1. Prepare all teeth with oil-free pumice, and rinse thoroughly for 15 seconds with water.~2. Wash thoroughly.~3. Etch enamel surface with 37% phosphoric acid for 15 seconds.~4. Rinse the etched surface for 20 seconds to remove the acid and precipitates that might have formed during the etching procedure.~5. Activate the capsule and immediately mix in an amalgamator. Do not click with applicator before you mix.~6. Immediately place into capsule applicator and click trigger until paste is seen through the nozzle~7. Light cure each increment for 20 seconds.
Study NCT05234112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community mobilisation for hrHPV self-testing
Description: use of social media, written media, theatre and other sources of communication to reach women, and relatives, to convince them of importance of screening.
Study NCT06508385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercise
Description: Breathing exercises will include;~1. Correct posture and sitting~2. Nose opening techniques~3. Diaphragmatic breathing, which consists of continuous and deep nasal inspiration with movement of the abdominal region and diaphragm~4. Main Breathing exercise (during 5 minutes)=inspiration (during 5 seconds) + expiration (during 15 seconds).
Study NCT06508385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: Breathing exercises will include;~1. Correct posture and sitting~2. Nose opening techniques~3. Diaphragmatic breathing, which consists of continuous and deep nasal inspiration with movement of the abdominal region and diaphragm~4. Main Breathing exercise (during 5 minutes)=inspiration (during 5 seconds) + expiration (during 15 seconds).
Study NCT06599177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational leaflet
Description: An informational leaflet describing:~* Information on benefits to which they are entitled and how to receive them.~* Information and linkage to support services in the community.~* Information on how to obtain health care materials (insured, uninsured).~* Information on relevant support associations/voluntary groups in the community.~* Information on employment programs.~* Activation of patient\&#39;s supportive social network/or referral to home help programs if they are a lonely person or in need of support.~* Individualized assessment of the patient\&#39;s needs.~* Design of a plan for individualised psychosocial intervention (focus personal intervention).~* Patient education about existing social support networks in the community and how to find them.~* Educate patients about available resources in the community (benefits, services).~* Patient referral/advocacy to community services.
Study NCT06599229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: myocardial contrast echo
Description: Vasodilator stress myocardial contrast echocardiography will be performed at baseline and within 4 months of reaching target dose of a cardiac myosin inhibitor.
Study NCT06594965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20106
Description: HS-20106 administered subcutaneously every 4 weeks for up to 6 cycles. Eligible participants may be able to continue to receive subcutaneously administered HS-20106 after completing 6 cycles in the extended treatment period.
Study NCT06590844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable coenzyme I
Description: On the first day, we will treat patients with Tybo Sulsintilimab ® 200mg IV and Dalutin ® Bevacizumab 15mg/kg IV every 21 days. The first to third days were treated with injectable coenzyme I, 100mg/day IV, every 21 days as a cycle.
Study NCT05234112 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: hrHPV self-testing
Description: use of swabs that women insert in the vagina for taking sufficient material for testing for hrHPV. For women who are not confident to perform this this nurses provide assistance.
Study NCT05234112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up after testing
Description: based on the results of the test, follow-up is offered. In case of hrHPV negative test, retesting after five years. In case of hrHPV positive test, VIA in a nearby clinic. Women have to be motivated to adhere to follow-up
Study NCT05234112 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VIA
Description: Test offers insight into existence of dysplasia of the cervix by colouring the transition area
Study NCT06589622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment
Description: Caries excavation with hand instruments only and restoration with Glass ionomer filling
Study NCT06589622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hall technique
Description: Crown placement without tooth preparation
Study NCT06592235 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06594822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic plus standard treatment
Description: Bacillus clausii, 5ml ampule containing 2 billion spores, given orally once daily
Study NCT06594822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: diclofenac 50 mg twice a day, prednisone 5mg once daily, methotrexate 10mg once weekly or sulfasalazine 500 twice daily
Study NCT05234112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermo-ablation or cryotherapy for dysplasia
Description: Women with identified dysplasia lesions are offered immediate therapy to remove the infected superficial surface of the cervix
Study NCT05234112 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pap smear cytology
Description: Cytology for identification of abnormal cells in the cervix, and classification of stages of dysplasia or pre-cancerous lesions
Study NCT06253091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robit-assist extraperitoneal laparoscopic radical cystectomy
Description: robit-assist laparoscopic radical cystectomy was performed extraperitoneal
Study NCT04906408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena
Description: Incisions will be dressed with closed incisional negative pressure wound therapy
Study NCT04906408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prineo
Description: Incisions will be dressed with Prineo
Study NCT04906408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Incisions will be dressed with bacitracin/xeroform
Study NCT06425874 — intervention group
Intervention type: PROCEDURE
Intervention: Breast-conserving surgery
Description: Breast-conserving surgery
Study NCT06425874 — intervention group
Intervention type: PROCEDURE
Intervention: Mastectomy
Description: Mastectomy without reconstruction
Study NCT06425874 — intervention group
Intervention type: PROCEDURE
Intervention: Mastectomy with reconstruction
Description: Any type of reconstruction(include implant and autologous)
Study NCT05094505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise in normoxia
Description: Exercise at sea level, 3 sessions per week, during a 8-week period intervention and will consist in 60 min on an ergometer, of continuous moderate and high intensity interval training. . All exercise testing and training sessions will be carried out at the same time of day (± 2 hours) and visits will be separated by at least 48h of recovery.
Study NCT05094505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Control diet: diet plans will be individualized and energy-content prescriptions will be constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions will be 20% of energy from fat, 20% from protein and 60% from carbohydrates for the low-fat diet during the 8 weeks. Diets emphasis on low-glycemic index foods and limited saturated fat to 10% of energy. Participants will meet individually with a dietitian two times for 8 weeks and should start the dietary intervention along with the intervention with exercise.